HAGLR

Summary

HAGLR (HOXD antisense growth-associated long non-coding RNA, HGNC:43755) is a long non-coding RNA gene on chromosome 2q31.1.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43755
Approved symbol	HAGLR
Name	HOXD antisense growth-associated long non-coding RNA
Location	2q31.1
Locus type	RNA, long non-coding
Status	Approved
Aliases	Mdgt, MIR7704HG, STEEL
Ensembl gene	ENSG00000224189
Ensembl biotype	lncRNA
OMIM	618209
Entrez	401022
RNAcentral	URS000075C93D — lncRNA, 3812 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 50 — 50 lncRNA

ENST00000413969, ENST00000416928, ENST00000417086, ENST00000425005, ENST00000436126, ENST00000447538, ENST00000452365, ENST00000456876, ENST00000546798, ENST00000547207, ENST00000549329, ENST00000552156, ENST00000642267, ENST00000643050, ENST00000644334, ENST00000645228, ENST00000669485, ENST00000843190, ENST00000843191, ENST00000843193, ENST00000843195, ENST00000843197, ENST00000843198, ENST00000843199, ENST00000843200, ENST00000843201, ENST00000843202, ENST00000843203, ENST00000843204, ENST00000843205, ENST00000843206, ENST00000843207, ENST00000843208, ENST00000843209, ENST00000843210, ENST00000843211, ENST00000843212, ENST00000843213, ENST00000843214, ENST00000843215, ENST00000843216, ENST00000843217, ENST00000843218, ENST00000843219, ENST00000843220, ENST00000843221, ENST00000843222, ENST00000843223, ENST00000843224, ENST00000843225

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000413969 — 4 exons

Exon	Start	End
ENSE00001618987	176176535	176176692
ENSE00001693783	176177332	176177494
ENSE00003816218	176178015	176178099
ENSE00003826936	176164051	176164109

Expression profiles

Bgee: expression breadth ubiquitous, 195 present calls, max score 95.43.

FANTOM5 (CAGE): breadth broad, TPM avg 3.1371 / max 177.7275, expressed in 631 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
31958	2.6528	578
31956	0.2778	45
31957	0.0934	39
31959	0.0899	44
31955	0.0232	11

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	95.43	gold quality
sperm	CL:0000019	95.06	gold quality
lower lobe of lung	UBERON:0008949	93.66	gold quality
right testis	UBERON:0004534	93.42	gold quality
left testis	UBERON:0004533	93.28	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	92.39	gold quality
spinal cord	UBERON:0002240	92.23	gold quality
testis	UBERON:0000473	92.02	gold quality
corpus epididymis	UBERON:0004359	91.76	gold quality
mucosa of sigmoid colon	UBERON:0004993	91.49	gold quality
colonic mucosa	UBERON:0000317	91.11	gold quality
kidney epithelium	UBERON:0004819	90.26	silver quality
oviduct epithelium	UBERON:0004804	90.25	gold quality
caput epididymis	UBERON:0004358	90.20	gold quality
seminal vesicle	UBERON:0000998	88.43	gold quality
adult organism	UBERON:0007023	86.29	gold quality
inferior vagus X ganglion	UBERON:0005363	86.00	gold quality
rectum	UBERON:0001052	85.44	gold quality
colonic epithelium	UBERON:0000397	85.09	gold quality
cauda epididymis	UBERON:0004360	84.80	gold quality
right uterine tube	UBERON:0001302	84.69	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.54	gold quality
mucosa of transverse colon	UBERON:0004991	83.87	gold quality
Brodmann (1909) area 46	UBERON:0006483	81.54	gold quality
corpus callosum	UBERON:0002336	81.52	gold quality
adult mammalian kidney	UBERON:0000082	81.28	gold quality
germinal epithelium of ovary	UBERON:0001304	80.67	silver quality
kidney	UBERON:0002113	80.61	gold quality
fallopian tube	UBERON:0003889	80.32	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.74	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	14.06

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 34)

• Study found that the expression level of HOXD-AS1 was significantly increased in bladder cancer tissues and cells and suggested that HOXD-AS1 may act as an oncogene involved in the bladder cancer carcinogenesis. (PMID:27328915)
• Our results suggest that HAGLR is an important regulator of non-small cell lung cancer cell proliferation and invasion, perhaps by regulating fatty acid synthase. Therefore, targeting HAGLR may be a possible therapeutic strategy for non-small cell lung cancer. (PMID:28443464)
• our data elucidate that knockdown of HOXD-AS1 dramatically suppresses gastric cancer cell growth by inactivating the Janus kinase 2/signal transducer and activator of transcription 3 pathway in vitro and in vivo, contributing to a better understanding of gastric cancer pathogenesis and providing a possible theoretical foundation for long non-coding RNA-directed diagnosis and therapy against this disease. (PMID:28475004)
• our findings indicate that HOXD-AS1 promotes proliferation, castration resistance, and chemo-resistance in prostate cancer by recruiting WDR5. (PMID:28487115)
• HOXD-AS1 expression was involved in tumor-node-metastasis stages, lymphovascular invasion, lymph node metastasis, as well as recurrence. HOXD-AS1 knockdown remarkably suppressed cervical cancer cell proliferation, colony formation capacity, and the Ras/ERK signaling pathway in vitro. (PMID:29228418)
• HOXD-AS1 promoted cell proliferation. (PMID:29239819)
• these results provide a comprehensive analysis of the role of HOXD-AS1 in glioma cells and offer important clues to understand the key roles of competing endogenous RNA (ceRNA) mechanisms in human glioma. (PMID:29341117)
• HOXDAS1 functioned as a competing endogenous RNA for miR217. In conclusion, the present study demonstrated that HOXDAS1 may promote colorectal cancer (CRC) progression and metastasis by competing for miR217. In addition, HOXDAS1 may be considered an indicator of prognosis in patients with CRC (PMID:29749477)
• HOXD-AS1 could interact with EZH2, and then repress p57 expression, to aggravate osteosarcoma oncogenesis. (PMID:30119259)
• The study in vitro suggested reduced HOXD-AS1 expression inhibited papillary thyroid cancer cell proliferation, migration, and invasion, and promoted cell-cycle arrest. In conclusion, HOXD-AS1 is a biomarker for predicting clinical progression in papillary thyroid cancer (PMID:30317670)
• HOXD-AS1 participates in the development and progression of preeclampsia by regulating trophoblast proliferation via the MAPK pathway. (PMID:30575894)
• HOXD-AS1 is upregulated in human breast cancer.HOXD-AS1 promotes breast cancer cell proliferation and cell cycle progression.HOXD-AS1 serves as a competing endogenous RNA to regulate miR-421 expression in breast cancer. (PMID:30730081)
• HOXD-AS1/miR-186-5p/PIK3R3 is a novel pathway to promote cell migration, invasion, and epithelial-mesenchymal transition in epithelial ovarian cancer (PMID:30823895)
• Nuclear lncRNA HOXD-AS1 suppresses colorectal carcinoma growth and metastasis via inhibiting HOXD3-induced ITGB3 transcriptional activation and MAPK/AKT signaling. (PMID:30823921)
• HOXD-AS1: a novel oncogenic long intergenic non-coding RNA in humans. (PMID:31002165)
• HAGLR was frequently down-regulated in lung adenocarcinoma (LUAD). Decreased HAGLR expression was clinically associated with shorter survival. HAGLR could physically interact with DNMT1, and recruit DNMT1 on E2F1 promoter to increase local DNA methylation. HAGLR promoted LUAD progression by recruiting DNMT1 to modulate the promoter methylation and expression of E2F1. (PMID:31194977)
• Silencing of long noncoding RNA HOXD-AS1 inhibits proliferation, cell cycle progression, migration and invasion of hepatocellular carcinoma cells through MEK/ERK pathway. (PMID:31231887)
• Elevated HAGLR expression is associated with epithelial-mesenchymal transition and metastatic potential in esophageal cancer. (PMID:31311326)
• Long Noncoding RNA HOXD-AS1 Promotes the Proliferation, Migration, and Invasion of Colorectal Cancer via the miR-526b-3p/CCND1 Axis. (PMID:32640404)
• HOXD-AS1 facilitates cell migration and invasion as an oncogenic lncRNA by competitively binding to miR-877-3p and upregulating FGF2 in human cervical cancer. (PMID:32977766)
• LncRNA HAGLR exacerbates hepatocellular carcinoma through negatively regulating miR-6785-5p. (PMID:33015776)
• Spliceosome-Associated microRNAs Signify Breast Cancer Cells and Portray Potential Novel Nuclear Targets. (PMID:33143250)
• HAGLR aggravates neuropathic pain and promotes inflammatory response and apoptosis of lipopolysaccharide-treated SH-SY5Y cells by sequestering miR-182-5p from ATAT1 and activating NLRP3 inflammasome. (PMID:33626373)
• LncRNA-HAGLR motivates triple negative breast cancer progression by regulation of WNT2 via sponging miR-335-3p. (PMID:34375306)
• Long noncoding RNA HAGLR sponges miR-338-3p to promote 5-Fu resistance in gastric cancer through targeting the LDHA-glycolysis pathway. (PMID:34658120)
• Exosomal long noncoding RNA HOXD-AS1 promotes prostate cancer metastasis via miR-361-5p/FOXM1 axis. (PMID:34864822)
• Knockdown of lncRNA HAGLR promotes Treg cell differentiation through increasing the RUNX3 level in dermatomyositis. (PMID:35064420)
• LncRNA HOXD-AS1 promotes oral squamous cell carcinoma by sponging miR-203a-5p. (PMID:35152529)
• Long noncoding RNA HOXD-AS1 promotes the progression of pancreatic cancer through miR-664b-3p/PLAC8 axis. (PMID:35279480)
• LncRNA HAGLR May Aggravate Melanoma Malignancy Via miR-4644/ASB11 Pathway. (PMID:36735150)
• LncRNA HAGLR silencing inhibits IL-1beta-induced chondrocytes inflammatory injury via miR-130a-3p/JAK1 axis. (PMID:36918905)
• Long non-coding RNA Homeobox D gene cluster antisense growth-associated long noncoding RNA/microRNA-182-5p/Homeobox protein A10 alleviates postmenopausal osteoporosis via accelerating osteoblast differentiation of bone marrow mesenchymal stem cells. (PMID:37752532)
• HAGLR, stabilized by m6A modification, triggers PTEN-Akt signaling cascade-mediated RPE cell pyroptosis via sponging miR-106b-5p. (PMID:38088496)
• LncRNA HAGLR regulates gastric cancer progression by regulating the miR-20a-5p/E2F1 axis. (PMID:39172101)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.